Health Care Equipment

SWS Medical

SWS Medical released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 229.63 M, actual EPS CNY 0.1705

SWS Medical to Release FY2026 Q1 Earnings Report on April 30 After-Market BJT

SWS Medical to release FY2025 earnings report on April 30 During-Market BJT, forecast revenue CNY 715 M, EPS CNY 0.44

SWS Medical released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 222.62 M, actual EPS CNY 0.1345

SWS Medical released FY2025 Annual Earnings on February 27 During-Market (BJT), actual revenue CNY 806.91 M (forecast CNY 715 M), actual EPS CNY 0.4589 (forecast CNY 0.44)

SWS Medical released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 227.04 M, actual EPS CNY 0.1538

SWS Medical released FY2025 9 Months Earnings on October 28 During-Market BJT, actual revenue CNY 584.29 M, actual EPS CNY 0.3257

SWS Medical FY2025 Q3 Earnings Release on October 29 During-Market (BJT)

SWS Medical released FY2025 Semi-Annual Earnings on August 19 After-Market (BJT), actual revenue CNY 357.25 M, actual EPS CNY 0.1713

SWS Medical released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 167.99 M, actual EPS CNY 0.0556

SWS Medical to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Shanwaishan Shareholder Reduces Holdings by 850,300 Shares

Shanwaishan Receives Utility Patent for Blood Dialysis Leak Detection Device

Shanwai Shan Increased R&D Investment to 54.2422 Million Yuan in 2024, Registered 6 Software Copyrights

Zhuhaixiuheng Completes 减持 Plan for Shanwaishan

Shareholders Plan to Reduce Holdings in Shanwaishan

Shanwaishan Shareholders Plan to Reduce Shareholding

Shanwai Shan's Net Profit Down 63.55% in 2024

Shanwai Shan's Revenue and Net Profit Growth in Q1 2025

SWS Medical released FY2025 Q1 earnings on April 21 After-Market BJT, actual revenue CNY 189.26 M, actual EPS CNY 0.1162

688410

SWS Medical, based in Chongqing, China, will showcase its blood purification solutions at the Dubai World Health (WHX) Expo from February 9-12, 2026. This marks the company's seventh consecutive year at the event, where they will be located at Booth N°37.D70-01 to engage with industry leaders, partners, and clients, highlighting their commitment to the global healthcare community.

Unusual Whales

SWS Medical to showcase blood purification solutions at Dubai WHX Expo from Feb 9-12, 2026. Booth N°37.D70-01.

SWS Medical will showcase its next-generation blood purification solutions at the Dubai World Health Expo 2026, marking its seventh consecutive participation. The company will exhibit its SWS-4000 and SWS-6000 dialysis machines, which feature advanced monitoring and safety technologies. SWS Medical, a leader in China's medical device sector, aims to strengthen its global position in blood purification. The company has also established a strategic partnership with a Middle Eastern medical provider to enhance healthcare innovation. SWS Medical is publicly listed on the STAR Market in China and adheres to international quality standards.

prnewswire

22:00 ETSWS Medical Brings Next-Generation Blood Purification Solutions to WHX Dubai 2026

SWS Medical, a leading Chinese provider of blood purification solutions, will showcase its innovative products at MEDICA 2025 in Düsseldorf, Germany. With over 20 years of experience, SWS is the top Chinese exporter of dialysis equipment, holding significant market shares in China. At MEDICA, SWS will present advanced dialysis technologies, including the SWS-6000 and SWS-5000 models, and its comprehensive range of products designed to improve treatment outcomes and workflow efficiency.

20:00 ET
			
			
			
				
					El líder de la industria de diálisis de China presentará soluciones de vanguardia en MEDICA 2025

000538

002614

On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Healthcare' Applications." Several A-share companies, such as SWS Medical, Yunnan Baiyao, and EASEPAL, have already laid out plans in the "Artificial Intelligence + Healthcare" field. The implementation opinions clarify the direction of industry support and key application areas, bringing new business expansion opportunities to related listed companies and aiding in performance growth

Wallstreetcn

Yunnan Baiyao

EASEPAL

"Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

SWS Medical announced that its revenue for the third quarter was 227 million yuan, a year-on-year increase of 61.66%; net profit was 49.448 million yuan, a year-on-year increase of 205.50%. Revenue for the first three quarters was 584 million yuan, a year-on-year increase of 39.79%; net profit was 104 million yuan, a year-on-year increase of 68.68%

Zhitong

SWS Medical: Net profit for the third quarter was 49.4488 million yuan, a year-on-year increase of 205.50%

SWS Medical announced that its shareholder, Dajiankang, intends to reduce its holdings by no more than 12.8526 million shares, accounting for no more than 4%. The director and deputy general manager, Ren Yingxiang, intends to reduce his holdings by no more than 249,500 shares, accounting for no more than 0.08%

SWS Medical shareholders plan to reduce their holdings by no more than 4.08%

On the evening of August 19th, SWS Medical disclosed its 2025 semi-annual report, showing that the company achieved operating revenue of 357 million yuan in the first half of the year, a year-on-year increase of 28.72%; the net profit attributable to the parent company was 55.0386 million yuan, a year-on-year increase of 20.28%. The basic earnings per share were 0.1713 yuan. During the reporting period, the company's product market share continued to increase, driving steady growth in sales revenue of blood purification equipment; the sales revenue of self-produced blood purification consumables saw a significant increase

SWS Medical: Net profit for the first half of the year was 55.0386 million yuan, a year-on-year increase of 20.28%

According to the announcement from SWS Medical, on June 6, 2025, the company received a "Notification of the Implementation Results of the Share Reduction Plan" from its shareholder Zhuhai Xiuheng. During this share reduction plan period, Zhuhai Xiuheng cumulatively reduced its holdings by 3.2132 million shares through centralized bidding, accounting for 1% of the company's total share capital. The time period for this share reduction plan has now expired

SWS Medical shareholders Zhuhai Xiuheng have cumulatively reduced their holdings in the company by 1%

Chinese blood purification leader, SWS Medical, is set to take part in Brazil's Hospitalar event from May 20 to 23, 2025, at Booth H-55. With over 20 years of experience, SWS has established itself as a prominent entity in this sector.

SWS Medical, a Chinese blood purification provider, showcased at Hospitalar event in Brazil, marking two decades of leadership.

According to the announcement from SWS Medical, shareholders Da Jiankang and Li Yuanjiankun plan to reduce their holdings of the company's shares by no more than 12.8526 million shares due to their own funding needs, through centralized bidding or block trading. The total reduction will not exceed 4% of the company's total share capital and will be implemented within three months after the announcement of this reduction plan, from May 30, 2025, to August 27, 2025

SWS Medical shareholders Dajiankang and Liyuan Jiankun plan to reduce their holdings by no more than 4% in total

SWS Medical(688410.SH)